The National Cancer Institute (NCI) seek parties interested in collaborative research and/or licensing to further develop neutralizing nanobodies targeting Lassa virus as a possible treatment of Lassa virus infections.
Scientists at the National Cancer Institute (NCI) discovered that the cyclic peptide recifin inhibits the activity of tyrosyl-DNA phosphodiesterase 1 (TDP1), a molecular target for the sensitization of cancer cells to the topoisomerase 1 (TOP1) inhibitor camptothecin and its chemotherapeutic derivatives – such as topotecan and irinotecan. NCI seeks research co-development partners and/or licensees for the development of recifin and its analogues as new chemosensitizing agents in adjunct therapies to enhance the sensitivity of cancer cells to topotecan, irinotecan and related chemotherapeutic agents.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for an HLA-A*01:01 restricted human T-cell receptor recognizing the NRAS Q61K hotspot mutation for development of T cell immunotherapies against multiple cancers, including melanoma.
The National Cancer Institute (NCI) and the National Institute of Child Health and Human Development (NICHD) seek research co-development partners and/or licensees for an antiviral treatment that can target SARS-Cov-2 replication in Covid-19 patients.
Researchers at the NCI seek licensing and/or co-development research collaborations for an anti-viral polypeptide, Griffithsin, and its antiviral use against Hepatitis C, Severe Acute Respiratory Syndrome (SARS), H5N1, or Ebola.
Researchers at the National Cancer Institute (NCI) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) have developed novel heterocyclic scaffold-based inhibitors of the polo-box domain (PBD) of Polo-like kinase 1 (Plk1). These compounds effectively arrest mitotic progression and cell proliferation in cell-based assays. The National Institutes of Health (NIH) seeks licensing and/or co-development research collaborations to further develop these inhibitors for the treatment of cancer.
The National Cancer Institute (NCI) seeks licensees for a method of high-throughput generation of induced pluripotent stem cells carrying antigen-specific T cell receptors from tumor infiltrated lymphocytes.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a novel method for isolation and construction of neoantigen-reactive T-cell receptors (TCRs) from peripheral blood lymphocytes (PBL) of cancer patients. This method generates accurate scoring of single T cells from tumors, as well as facilitates identification and reconstruction of unknown TCRs for immunotherapy.
Researchers at the National Cancer Institute (NCI) have developed a novel method for identifying neoantigen reactive T cells and T cell receptors (TCRs), isolated from fresh tumors of common epithelial cancers. This highly specific and sensitive method allows rapid determination of the neoantigen reactive TCR sequences and can be very useful to translate this information into TCR-engineered T-cell populations for immunotherapy without the need to grow tumor infiltrating T-cells and expensive, time-consuming screening. The NCI seeks research co-development partners and/or licensees for this invention.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a method to isolate and sequence tumor reactive T Cell Receptors (TCRs) from cancer specific T cells using calcium ion (Ca2+) flux as the marker of TCR ligation and activation.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for small molecules that inhibit histone lysine demethylases (KDMs). These compounds may be effective therapeutics for Rhabdomyosarcoma (RMS) and other cancers.
Researchers at the National Cancer Institute (NCI) have isolated seven monoclonal antibodies that bind to the human epidermal growth factor receptor variant III (EGFRvIII) but not wildtype EGFR. The NCI seeks research co-development partners or licensees for monoclonal antibodies that specifically target cancer-expressed EGFR.
Adoptive T Cell Therapy (ACT) has proven to effectively treat established tumors. This treatment consists of harvesting Tumor Infiltrated Lymphocytes (TIL) which specifically recognize cancer, expanding the tumor-specific TIL in vitro, and then reinfusing these cells into the patient for treatment. Both these lymphocytes and their T cell receptors (TCR) are valuable for cancer immunotherapy. Inventors from the National Cancer Institute (NCI) have developed an improved method to identify tumor-specific TCRs by reprogramming TIL into stem cells. This invention is available to license further development.
Researchers at the National Cancer Institute (NCI) have developed several novel small-molecule inhibitors directed against HPPK, a bacterial protein, as potential antimicrobial agents. The NCI seeks co-development partners or licensees to further develop these novel small-molecule HPPK inhibitors as broad-spectrum bactericidal agents.
The National Cancer Institute (NCI) seeks licensing and/or co-development of an adoptive cellular therapeutic modality that targets CCR4, which is overexpressed in certain lymphoid malignancies as well as solid tumors.
Chimeric Antigen Receptors (CARs) are engineered proteins that can be used in a therapeutic capacity when expressed by an immune cell (e.g., a T cell). Specifically, CARs comprise a targeting domain (such as an antibody or binding fragment thereof) as well as domains that activate immune cells. By selecting a targeting domain that binds to a protein that is selectively expressed on a cancer cell, it is possible to target immune cells to the cancer cells. Upon binding to the target cell, the immune cells are activated, leading to the destruction of the cancer cell. This therapeutic approach holds great promise, as evidenced by the recent FDA-approval of CAR-T cell therapies, KYMRIAH and YESCARTA, both of which target CD19.
Cancer therapies that specifically target Glypican 2 (GPC2) are strong therapeutic candidates for pediatric patients with neuroblastoma and other GPC2 expressing cancers. The inventors at the National Cancer Institute (NCI) have developed and isolated two new antibodies that target GPC2 (CT3 and CT5) that are available for licensing and co-development.